Car T Kymriah denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Kymriah

Kymriah (tisagenlecleucel) is subject to mandatory prior authorization under UnitedHealthcare's specialty drug management program. This is a standard utilization-management requirement for high-cost therapies — it is not itself a denial of coverage. However, when a prior-authorization request is denied, or when treatment was initiated without authorization (in a true emergency or through a process error), the resulting claim denial requires a formal appeal.

## Why This Denial Is Appealable

Prior-authorization denials for FDA-approved therapies are among the most frequently reversed on appeal, particularly when the clinical documentation submitted at authorization was incomplete. An appeal allows you to supplement the record with everything UHC's coverage policy requires. Retroactive authorization is also available in qualifying circumstances (e.g., urgent/emergent situations).

## Federal Appeal Framework

• Internal appeal: File within the deadline on the Explanation of Benefits. If authorization was denied pre-service, you may simultaneously request expedited review.
• Expedited prior-authorization review: Federally required when the standard timeline could jeopardize the patient's health. Insurers must respond within 72 hours on an expedited urgent-care request.
• External Independent Review (ACA §2719): Available after internal exhaustion; also available after 72 hours if an expedited internal appeal has not been resolved. The IRO decision is binding on the plan.
• ERISA §503: Employer-plan beneficiaries have full-and-fair review rights; the external-review window is approximately four months.

## Documentation to Gather

1. Original authorization request and denial letter — know exactly which criteria UHC said were unmet. 2. Diagnosis and indication match — pathology, staging, molecular/cytogenetic workup confirming alignment with the FDA-approved indication. 3. Prior-treatment history — complete records with dates, regimens, responses, and reasons for discontinuation. 4. Facility certification — confirmation that the administering center is an authorized CAR-T treatment site. 5. Prescriber medical-necessity letter — detailed letter from the treating specialist addressing each unmet criterion cited in the denial. 6. Current clinical-severity documentation — performance status, disease-burden assessments, and any time-sensitivity factors.

## Criteria-Mapping Structure

Obtain UHC's published coverage policy for tisagenlecleucel. Create a table with each authorization criterion in the left column and the corresponding chart evidence in the right column. Quote the denial letter's specific objections and address each one directly. Where UHC cites guideline requirements (e.g., referencing the applicable NCCN guideline), pull the current guideline edition and document exactly how your patient's situation satisfies it. Submit this table as an exhibit to the appeal letter so the reviewer has an unambiguous criterion-by-criterion resolution.